Role and value of inflammatory markers in brain tumors: A case controlled study

Brain tumor is one of the most devastating diseases in the world. The Pathogenesis is vary in multiple aspect of mechanism. The tumor microenvironment contains many different noncancerous cell types in addition to cancer cells. Inflammation is thought to be one of the factors that influence the oncogenesis process in brain tumors.

This study is a case controlled analytical study that analyzes the relationship between levels of inflammatory markers with the type of brain tumor. Samples of 35 people were then categorized according to the variables above and analyzing to measure its significance.

Based on demografic study, most sample was male with age was 41-50 years It was found that high levels of procalcitonin were found in the case of glioma brain tumors. Procalcitonin level was considered a significant marker in predicting the severity of a brain tumor (p < 0.005). There was no significant value between the C-Reactive Protein and Neutrophyl-Lymphocyte ratio values for brain tumors.

Abnormal inflammation is a characteristic of malignant cancers and malignant transformation of low-grade gliomas and other brain tumor. Inflammation-induced activation of transcription factors contributes to the survival and rapid growth of glioma cells.

As in other malignant cancers, inflammation may contribute to tumor progression. Biomarkers based on inflammation, such as the classical example of Procalcitonin and C-reactive protein, have been used to assess prognosis of glioma patients. These results should be validated and extended in larger clinical studies.